Long‐Term Survival With Olaparib Maintenance Therapy in Metastatic Pancreatic Carcinoma of a Patient Harboring Germline BRIP1 and ATM Mutations
Ruemu E. Birhiray, Maya N. Birhiray, Samuel L. Ranger, Vincent L. Flanders · 2025
Read Long‐Term Survival With Olaparib Maintenance Therapy in Metastatic Pancreatic Carcinoma of a Patient Harboring Germline BRIP1 and ATM Mutations by Ruemu E. Birhiray, Maya N. Birhiray, Samuel L. Ranger, Vincent L. Flanders (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12747106.txt.
Description
Ruemu Birhiray and three co-authors report a striking pancreatic cancer case in a 2025 paper. Pancreatic cancer kills about fifty thousand Americans a year and rarely allows long survival. A small subgroup carries inherited DNA repair defects that open a drug door.
The patient, a seventy-two-year-old woman, carried inherited mutations in two repair genes. Those defects leave tumors unable to fix certain DNA damage. After strong chemotherapy she reached complete remission. A maintenance pill that blocks DNA repair in cancer cells has kept her in remission for over forty months. That drug is approved for a related mutation group, not hers. The case argues for widening access to repair-targeted therapy in pancreatic cancer.
Catalog record
| CREATOR | Ruemu E. Birhiray, Maya N. Birhiray, Samuel L. Ranger, Vincent L. Flanders |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |